Polyvinylpyrrolidone Assisted One-Pot Synthesis of Size-Tunable Cocktail Nanodrug for Multifunctional Combat of Cancer

References

• Ashrafizadeh M, Delfi M, Zarrabi A, et al. Stimuli-responsive liposomal nanoformulations in cancer therapy: pre-clinical & clinical approaches. J Control Release. 2022;351:50–80. doi:10.1016/j.jconrel.2022.08.001
   PubMed Web of Science ®Google Scholar
• Dessale M, Mengistu G, Mengist HM. Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosis. Int j Nanomed. 2022;17:3735. doi:10.2147/IJN.S378074
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013;170(1):15–40. doi:10.1016/j.jconrel.2013.04.020
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726. doi:10.1038/nrc3599
   PubMed Web of Science ®Google Scholar
• Chen M, Chen B, Ge X, Ma Q, Gao S. Targeted nanodrugs to destroy the tumor extracellular matrix barrier for improving drug delivery and cancer therapeutic efficacy. Mol Pharmaceut. 2023;20(5):2389–2401. doi:10.1021/acs.molpharmaceut.2c00947
   PubMed Web of Science ®Google Scholar
• Duan C, Yu M, Xu J, Li B-Y, Zhao Y, Kankala RK. Overcoming cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother. 2023;162:114643. doi:10.1016/j.biopha.2023.114643
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnol. 2015;33(9):941–951. doi:10.1038/nbt.3330
   PubMed Web of Science ®Google Scholar
• Curtis LT, Frieboes HB. The tumor microenvironment as a barrier to cancer nanotherapy. Syst Biol Tumor Microenviron. 2016;2016:165–190.
   Google Scholar
• Kim SM, Faix PH, Schnitzer JE. Overcoming key biological barriers to cancer drug delivery and efficacy. J Control Release. 2017;267:15–30. doi:10.1016/j.jconrel.2017.09.016
   PubMed Web of Science ®Google Scholar
• Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma. Neuro-Oncology. 2015;18(1):27–36. doi:10.1093/neuonc/nov164
   PubMed Web of Science ®Google Scholar
• Majidinia M, Mirza‐Aghazadeh‐Attari M, Rahimi M, et al. Overcoming multidrug resistance in cancer: recent progress in nanotechnology and new horizons. IUBMB Life. 2020;72(5):855–871. doi:10.1002/iub.2215
   PubMed Web of Science ®Google Scholar
• Park H, Otte A, Park K. Evolution of drug delivery systems: from 1950 to 2020 and beyond. J Control Release. 2022;342:53–65. doi:10.1016/j.jconrel.2021.12.030
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Ma Z, He C, Wu Y, An Q. Designing cancer nanodrugs that are highly loaded, pH-responsive, photothermal, and possess a favored morphology: a hierarchical assembly of DOX and layer-by-layer modified rGO. Chin Chem Lett. 2019;30(2):489–493. doi:10.1016/j.cclet.2018.03.019
   Web of Science ®Google Scholar
• Barenholz YC. Doxil®—The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134. doi:10.1016/j.jconrel.2012.03.020
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou B, Zheng X, Wei J, Ji C, Yin M. Tumor microenvironment-activated multi-functional nanodrug with size-enlargement for enhanced cancer phototheranostics. Biomater. Sci. 2023;11(2):472–480. doi:10.1039/D2BM01604D
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang D, Jiang Z, et al. A Nanodrug-Enabled chemosensitization of cancer stem cells against tumor progression and metastasis. Chem Eng J. 2023;477:147121. doi:10.1016/j.cej.2023.147121
   Web of Science ®Google Scholar
• Nakamura H, Jun F, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Delivery. 2015;12(1):53–64. doi:10.1517/17425247.2014.955011
   PubMed Web of Science ®Google Scholar
• Shen Y, Bae YH. Tumour extravasation of nanomedicine: the EPR and alternative pathways. Adv Drug Delivery Rev. 2023;194:114707. doi:10.1016/j.addr.2023.114707
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang S. Advantages of nanomedicine in cancer therapy. A Rev ACS Applied Nano Mater. 2023;6:22594–22610. doi:10.1021/acsanm.3c04487
   Web of Science ®Google Scholar
• Wang C. Reconstituted lipid nanoparticles from cells/tissues for drug delivery in cancer. Mol Pharmaceut. 2023;20(6):2891–2898. doi:10.1021/acs.molpharmaceut.2c01033
   PubMed Web of Science ®Google Scholar
• Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy–Strategies and perspectives. J Control Release. 2016;240:489–503. doi:10.1016/j.jconrel.2016.06.012
   PubMed Web of Science ®Google Scholar
• Liu S, Khan AR, Yang X, Dong B, Ji J, Zhai G. The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy. J Control Release. 2021;335:1–20. doi:10.1016/j.jconrel.2021.05.012
   PubMed Web of Science ®Google Scholar
• Fulfager AD, Yadav KS. Understanding the implications of co-delivering therapeutic agents in a nanocarrier to combat multidrug resistance (MDR) in breast cancer. J Drug Delivery Sci Technol. 2021;62:102405. doi:10.1016/j.jddst.2021.102405
   Web of Science ®Google Scholar
• Wang H, Huang Y. Combination therapy based on nano codelivery for overcoming cancer drug resistance. Med Drug Discov. 2020;6:100024. doi:10.1016/j.medidd.2020.100024
   Google Scholar
• Liu S, Li R, Qian J, et al. Combination therapy of doxorubicin and quercetin on multidrug-resistant breast cancer and their sequential delivery by reduction-sensitive hyaluronic acid-based conjugate/d-α-tocopheryl poly (ethylene glycol) 1000 succinate mixed micelles. Mol Pharmaceut. 2020;17(4):1415–1427. doi:10.1021/acs.molpharmaceut.0c00138
   PubMed Web of Science ®Google Scholar
• Gao Q, Feng J, Liu W, et al. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Adv Drug Delivery Rev. 2022;188:114445. doi:10.1016/j.addr.2022.114445
   PubMed Web of Science ®Google Scholar
• Zong L, Cheng G, Liu S, Pi Z, Liu Z, Song F. Reversal of multidrug resistance in breast cancer cells by a combination of ursolic acid with doxorubicin. J Pharmac Biomed Analy. 2019;165:268–275. doi:10.1016/j.jpba.2018.11.057
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou J, Fu Y, et al. Deeply infiltrating iRGD‐graphene oxide for the intensive treatment of metastatic tumors through PTT‐mediated chemosensitization and strengthened integrin targeting‐based antimigration. Adv. Healthcare Mater. 2021;10(16):2100536. doi:10.1002/adhm.202100536
   Web of Science ®Google Scholar
• Wang C, Chen S, Yu F, et al. Dual‐channel theranostic system for quantitative self‐indication and low‐temperature synergistic therapy of cancer. Small. 2021;17(10):2007953. doi:10.1002/smll.202007953
   Web of Science ®Google Scholar
• Geng S, Zhao H, Zhan G, Zhao Y, Yang X. Injectable in situ forming hydrogels of thermosensitive polypyrrole nanoplatforms for precisely synergistic photothermo-chemotherapy. ACS Appl Mater Interfaces. 2020;12(7):7995–8005. doi:10.1021/acsami.9b22654
   PubMed Web of Science ®Google Scholar
• Niu C, Xu Y, An S, et al. Near-infrared induced phase-shifted ICG/Fe3O4 loaded PLGA nanoparticles for photothermal tumor ablation. Sci Rep. 2017;7(1):5490. doi:10.1038/s41598-017-06122-1
   PubMedGoogle Scholar
• Zhang X, Ma Y, Zhang X, Pang X, Yang Z. Bio-inspired self-assembled bacteriochlorin nanoparticles for superior visualization and photothermal ablation of tumors. Biomed Pharmacother. 2023;165:115014. doi:10.1016/j.biopha.2023.115014
   PubMed Web of Science ®Google Scholar
• Dai X, Li L, Li M, et al. One pot preparation of muti-mode nanoplatform to combat ovarian cancer. Biomed Pharmacother. 2023;165:115172. doi:10.1016/j.biopha.2023.115172
   PubMed Web of Science ®Google Scholar
• Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chin Chem Lett. 2023;34(2):107518. doi:10.1016/j.cclet.2022.05.032
   Web of Science ®Google Scholar
• Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16(1):173. doi:10.1186/s11671-021-03628-6
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Z, Liu L, et al. Redox homeostasis modulation using theranostic AIE nanoparticles results in positive-feedback drug accumulation and enhanced drug penetration to combat drug-resistant cancer. Mater Today Bio. 2022;16:100396. doi:10.1016/j.mtbio.2022.100396
   PubMedGoogle Scholar
• Chang Y, Cui P, Zhou S, et al. Metal-phenolic network for cancer therapy. J Drug Delivery Sci Technol. 2023;81:104194. doi:10.1016/j.jddst.2023.104194
   Web of Science ®Google Scholar
• Wang C, Chen S, Bao L, Liu X, Hu F, Yuan H. Size-controlled preparation and behavior study of phospholipid–calcium carbonate hybrid nanoparticles. Int J Nanomed. 2020;Volume 15:4049–4062. doi:10.2147/IJN.S237156
   Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine. 2016;11(6):673–692. doi:10.2217/nnm.16.5
   PubMed Web of Science ®Google Scholar
• Keyvani‐Ghamsari S, Khorsandi K, Gul A. Curcumin effect on cancer cells’ multidrug resistance: an update. Phytother Res. 2020;34(10):2534–2556. doi:10.1002/ptr.6703
   PubMed Web of Science ®Google Scholar
• Sagnou M, Novikov FN, Ivanova ES, et al. Novel curcumin derivatives as P-glycoprotein inhibitors: molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin. Eur J Med Chem. 2020;198:112331. doi:10.1016/j.ejmech.2020.112331
   PubMed Web of Science ®Google Scholar
• Chan LL-Y, McCulley KJ, Kessel SL. Assessment of cell viability with single-, dual-, and multi-staining methods using image cytometry. Cell Viability Assays. 2017;2017:27–41.
   Google Scholar
• Mirzaei S, Gholami MH, Hashemi F, et al. Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects. Drug Discovery Today. 2022;27(2):436–455. doi:10.1016/j.drudis.2021.09.020
   PubMed Web of Science ®Google Scholar
• Chen S-Q, Wang C, Song Y-Q, et al. Quercetin covalently linked lipid nanoparticles: multifaceted killing effect on tumor cells. ACS omega. 2020;5(46):30274–30281. doi:10.1021/acsomega.0c04795
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Błauż A, Möckel D, et al. Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur J Pharm Sci. 2012;45(4):421–428. doi:10.1016/j.ejps.2011.08.028
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature Mater. 2013;12(11):991–1003. doi:10.1038/nmat3776
   PubMed Web of Science ®Google Scholar
• Yin Q, Shen J, Zhang Z, Yu H, Li Y. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Delivery Rev. 2013;65(13–14):1699–1715. doi:10.1016/j.addr.2013.04.011
   PubMed Web of Science ®Google Scholar
• Kulshrestha A, Katara GK, Schneiderman S, et al. Targeting the pH regulators in the tumor microenvironment for ovarian cancer treatment. Clin Cancer Res. 2020;26(13):113. doi:10.1158/1557-3265.OVCA19-B64
   Web of Science ®Google Scholar
• Savic LJ, Schobert IT, Peters D, et al. Molecular imaging of extracellular tumor pH to reveal effects of locoregional therapy on liver cancer microenvironment. Clin Cancer Res. 2020;26(2):428–438. doi:10.1158/1078-0432.CCR-19-1702
   PubMed Web of Science ®Google Scholar
• Karimi M, Eslami M, Sahandi‐Zangabad P, et al. pH‐Sensitive stimulus‐responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(5):696–716. doi:10.1002/wnan.1389
   PubMed Web of Science ®Google Scholar
• Fang W, Yang J, Gong J, Zheng N. Photo- and pH-triggered release of anticancer drugs from mesoporous silica-coated. Pd@Ag Nanoparticles. 2012;22(4):842–848.
   Google Scholar
• Liu X, Wang C, Ma H, Yu F, Hu F, Yuan H. Water‐responsive hybrid nanoparticles codelivering ICG and DOX effectively treat breast cancer via hyperthermia‐aided DOX functionality and drug penetration. Adv. Healthcare Mater. 2019;8(8):1801486. doi:10.1002/adhm.201801486
   Web of Science ®Google Scholar
• Bhatt HN, Diwan R, Borrego EA, et al. A photothermal driven chemotherapy for the treatment of metastatic melanoma. J Control Release. 2023;361:314–333. doi:10.1016/j.jconrel.2023.08.005
   PubMed Web of Science ®Google Scholar
• Lu H, Stenzel MH. Multicellular tumor spheroids (MCTS) as a 3D in vitro evaluation tool of nanoparticles. Small. 2018;14(13):1702858. doi:10.1002/smll.201702858
   Web of Science ®Google Scholar
• Wang C, Wang Z, Chen S, et al. Modulation of aggregation‐caused quenching to aggregation‐induced emission: finding a biocompatible polymeric theranostics platform for cancer therapy. Macromol Rapid Communic. 2021;42(19):2100264. doi:10.1002/marc.202100264
   Web of Science ®Google Scholar
• Yu J, Wang L, Xie X, et al. Multifunctional nanoparticles codelivering doxorubicin and amorphous calcium carbonate preloaded with indocyanine green for enhanced chemo-photothermal cancer therapy. Int J Nanomed. 2023;Volume 18:323–337. doi:10.2147/IJN.S394896
   Web of Science ®Google Scholar
• Zhou J, Li K, Zang X, Xie Y, Song J, Chen X. Ros-responsive galactosylated-nanoparticles with doxorubicin entrapment for triple negative breast cancer therapy. Int J Nanomed. 2023;Volume 18:1381–1397. doi:10.2147/IJN.S396087
   Web of Science ®Google Scholar
• Xiong H, Wang C, Wang Z, Lu H, Yao J. Self-assembled nano-activator constructed ferroptosis-immunotherapy through hijacking endogenous iron to intracellular positive feedback loop. J Control Release. 2021;332:539–552. doi:10.1016/j.jconrel.2021.03.007
   PubMed Web of Science ®Google Scholar